Participating Faculty: Considerations for the Optimal Use of Immunoglobulin

This supplement to The American Journal of Managed Care discusses the appropriate and optimal use of immunoglobulin G (IgG). It reviews the use of IgG in immunodeficiency syndromes, discusses differences in IgG products (eg, formulations and routes of administration), and describes practical challenges related to IgG use for payers, practitioners, and patients. The content of this supplement is based on a review of scientific literature and discussions from an expert roundtable panel consisting of clinicians and managed care professionals.This supplement to The American Journal of Managed Care was supported by CSL Behring.

Moderator

Robert P. Navarro, PharmD

Clinical Professor, Department of Pharmaceutical Outcomes & Policy

University of Florida College of Pharmacy

Gainesville, Florida

Faculty

Mark Ballow, MD

Chief, Division of Allergy and Immunology

Department of Pediatrics

Women & Children’s Hospital of Buffalo

Buffalo, New York

State University of New York at Buffalo

School of Medicine and Biomedical Sciences

Buffalo, New York

Beckie Fenrick, PharmD, MBA

Senior Director, Medical Operations

Care Models and Affordability Solutions

Florida Blue

Jacksonville, Florida

Edmund J. Pezalla, MD, MPH

National Medical Director for Pharmacy Policy and Strategy

Aetna

Hartford, Connecticut

Disclosures

These participants report relationships with the following organizations:

Mark Ballow, MD

Consultant/Advisory Board: Baxter, CSL Behring, Grifols

Honoraria: Baxter, CSL Behring

Lecturer: Baxter

Beckie Fenrick, PharmD, MBA

Employee: Florida Blue

Edmund J. Pezalla, MD, MPH

Employee: Aetna

Robert P. Navarro, PharmD, reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Download PDF: Participating Faculty: Considerations for the Optimal Use of Immunoglobulin